FOXA2 activates HIF2α expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma

Yang, D; Li, Q; Lu, P; Wu, D; Li, W; Meng, X; Xing, M; Shangguan, W; Chen, B; Yang, J; Zhang, Z; Wang, Z; Huang, DCS; Zhao, Q

Author(s): Yang, D; Li, Q; Lu, P; Wu, D; Li, W; Meng, X; Xing, M; Shangguan, W; Chen, B; Yang, J; Zhang, Z; Wang, Z; Huang, DCS; Zhao, Q;
Details: Publication Year 2024-12-10,Volume 300,Issue #1,Page 105535
Journal Title: Journal of Biological Chemistry
Abstract: Renal cell carcinoma (RCC) is a frequent malignancy of the urinary system with high mortality and morbidity. However, the molecular mechanisms underlying RCC progression are still largely unknown. In this study, we identified FOXA2, a pioneer transcription factor, as a driver oncogene for RCC. We show that FOXA2 was commonly upregulated in human RCC samples and promoted RCC proliferation, as evidenced by assays of cell viability, colony formation, migratory and invasive capabilities, and stemness properties. Mechanistically, we found that FOXA2 promoted RCC cell proliferation by transcriptionally activating HIF2α expression in vitro and in vivo. Furthermore, we found that FOXA2 could interact with VHL (von Hippel‒Lindau), which ubiquitinated FOXA2 and controlled its protein stability in RCC cells. We showed that mutation of lysine at position 264 to arginine in FOXA2 could mostly abrogate its ubiquitination, augment its activation effect on HIF2α expression, and promote RCC proliferation in vitro and RCC progression in vivo. Importantly, elevated expression of FOXA2 in patients with RCC positively correlated with the expression of HIF2α and was associated with shorter overall and disease-free survival. Together, these findings reveal a novel role of FOXA2 in RCC development and provide insights into the underlying molecular mechanisms of FOXA2-driven pathological processes in RCC.
Publisher: Elsevier
Keywords: Foxa2; Hif2α; Vhl; cell proliferation; gene expression; renal cell carcinoma
Research Division(s): Blood Cells And Blood Cancer
PubMed ID: 38072043
Publisher's Version: https://doi.org/10.1016/j.jbc.2023.105535
Open Access at Publisher's Site: https://doi.org/10.1016/j.jbc.2023.105535
Terms of Use/Rights Notice: Refer to copyright notice on published article.
Documents: PIIS0021925823025632.pdf - (4.18MB, application/pdf)

Creation Date: 2024-01-16 09:41:01

Last Modified: 2024-01-16 09:56:00